NASDAQ · KURA
Kura Oncology, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for KURA: Nov 3, 2026
Kura Oncology, Inc. Common Stock is estimated to report earnings on 11/03/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 6 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.83. The reported EPS for the same quarter last year was $-0.85.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.83 | $-0.74 | $-0.99 | 6 |
| Dec 2026 | $-0.86 | $-0.80 | $-0.94 | 5 |
| Mar 2027 | $-0.63 | $-0.55 | $-0.71 | 2 |
| Jun 2027 | $-0.62 | $-0.54 | $-0.69 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · MarketBeat · RTTNews · The Motley Fool- Zacks · Oct 28, 9:00 AM EDTQiagen (QGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseQiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 27, 9:00 AM EDTWill Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should KnowKura Oncology (KURA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- MarketBeat · Oct 13, 8:02 PM EDTKura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin InhibitorIs Kintara Therapeutics A Hidden Gem?Kura Oncology (NASDAQ:KURA) and its newly formed affiliate Caspian Therapeutics outlined plans to develop KO-7246, an oral menin inhibitor, for diabetes, citing preclinical data that the companies said showed beta-cell expansion, improved gluc
- RTTNews · Oct 13, 10:30 AM EDTCaspian Therapeutics, Kura Oncology Outline Development Path For Diabetes Candidate KO-7246(RTTNews) – Caspian Therapeutics and Kura Oncology (KURA) outlined the development strategy for KO-7246, an oral menin inhibitor designed for diabetes and other chronic metabolic diseases. The companies highlighted new findings supporting the candidate's potential to restore the
- RTTNews · Sep 8, 7:12 AM EDTKura Oncology Names Jennifer Fulk CFO(RTTNews) – Kura Oncology, Inc. (KURA), on Tuesday appointed Jennifer Fulk as Chief Financial Officer, effective September 8.
- Zacks · Sep 1, 9:05 AM EDTKURA Stock Gains 37.6% in a Month: Here's What You Need to KnowKura's rising Komzifti sales, promising AML data and pipeline catalysts boost investor confidence and fuel KURA's gains.
- Zacks · Aug 31, 12:00 PM EDTKura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock?Kura Oncology (KURA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks · Aug 27, 10:48 AM EDTOncology Stocks to Add to Your Portfolio as Cancer Care EvolvesOncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.
- Zacks · Aug 26, 9:11 AM EDTCompany News for Aug 26, 2026Companies in The News Are: DKS,KURA,NVTS,WMT
- The Motley Fool · Aug 25, 12:17 PM EDTKura Oncology CEO Buys 100,000 Shares for $1.2 Million. Does This Large Buy Bode Well for Shares in 2026?The President and CEO acquired ~100,000 shares at $12.39 per share for a total transaction value of $1.2 million.
- BNK Invest · Aug 25, 11:09 AM EDTTuesday 8/25 Insider Buying Report: KURA, TTMIBargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money. Today
- RTTNews · Aug 25, 10:05 AM EDTCan Komzifti's Early Adoption Support Kura Oncology's Next Phase Of Growth?(RTTNews) – FDA approval is an important milestone, but it is patient adoption that ultimately determines a therapy's commercial success.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Kura Oncology, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.